Exploring the Relationship between Antioxidant Enzymes, Oxidative Stress Markers, and Clinical Profile in Relapsing-Remitting Multiple Sclerosis

被引:13
|
作者
Bizon, Anna [1 ]
Chojdak-Lukasiewicz, Justyna [2 ]
Budrewicz, Slawomir [2 ]
Pokryszko-Dragan, Anna [2 ]
Piwowar, Agnieszka [1 ]
机构
[1] Wroclaw Med Univ, Fac Pharm, Dept Toxicol, Borowska 211, PL-50556 Wroclaw, Poland
[2] Wroclaw Med Univ, Fac Med, Dept Neurol, Borowska 213, PL-50556 Wroclaw, Poland
关键词
relapsing-remitting multiple sclerosis; oxidative stress; antioxidants; GLUTATHIONE-PEROXIDASE; SUPEROXIDE-DISMUTASE; CATALASE; SELENIUM; ERYTHROCYTES; SERUM;
D O I
10.3390/antiox12081638
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We aimed to investigate the extent of alterations in the pro/antioxidant balance in the blood of patients with relapsing-remitting multiple sclerosis (RRMS) in relation to drug-modified therapy, gender, disability score, and disease duration. 161 patients (67 men and 94 women, aged 24-69 years, median 43.0) and 29 healthy individuals (9 men and 20 women, aged 25-68 years, median 41.0) were included in the study. We measured the activity of superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT) as well as the concentration of interleukin-6 (IL-6), lipid peroxidation parameters (LPO), total oxidant status (TOS), and total antioxidant capacity (TAS). The activity of SOD did not show any significant differences between patients with RRMS and the control group in our study. In contrast, significant decreased GPx activity and increased CAT activity was observed in the blood of patients with RRMS compared to the control group. Additionally, the activity of CAT was influenced by gender and the use of disease-modifying therapies. Disease-modifying therapies also affected the concentration of TOS, TAS, and LPO. Our studies indicated that enhancing GPx activity may be more beneficial to providing potential therapeutic strategies aimed at modulating antioxidant defenses to mitigate oxidative stress in this disease.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] The relationship between smoking and disease activity in patients with relapsing-remitting multiple sclerosis on immunomodulatory therapy
    Rakoca, Michal
    Tywoniuk, Anna
    Adamczyk-Sowa, Monika
    Kulakowska, Alina
    Koziarska, Dorota
    Kubicka-Baczyk, Katarzyna
    Jakubowicz-Lachowska, Dominika
    Wawrzyniak, Slawomir
    AKTUALNOSCI NEUROLOGICZNE, 2020, 20 (01): : 9 - 13
  • [42] Relationship Between the Theory of Mind and the Ability to Change of Perspective in Patients with Relapsing-Remitting Multiple Sclerosis
    Bruno, Diana
    Pagani Cassara, Fatima
    Sinay, Vladimiro
    Roca, Maria
    NEUROLOGY, 2016, 86
  • [43] Pattern of neuropsychological impairment and clinical correlates in relapsing-remitting multiple sclerosis
    Lozano-Soto, E.
    Gutierrez, R.
    Gonzalez-Prian, M.
    Gomez, A. J. Cruz
    Sanmartino, F.
    Moya Molina, M. A.
    Espinosa-Rosso, R.
    Forero, L.
    Gonzalez-Rosa, J. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 494 - 494
  • [44] In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
    Fianne L. P. Sips
    Francesco Pappalardo
    Giulia Russo
    Roberta Bursi
    BMC Medical Informatics and Decision Making, 22
  • [45] Relationship Between Retinal Layer Thickness and Disability Worsening in Relapsing-Remitting and Progressive Multiple Sclerosis
    Cellerino, Maria
    Priano, Luca
    Bruschi, Nicolo
    Boffa, Giacomo
    Petracca, Maria
    Novi, Giovanni
    Lapucci, Caterina
    Sbragia, Elvira
    Uccelli, Antonio
    Inglese, Matilde
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2021, 41 (03) : 329 - 334
  • [46] Reassessment of Blood Gene Expression Markers for the Prognosis of Relapsing-Remitting Multiple Sclerosis
    Hecker, Michael
    Paap, Brigitte Katrin
    Goertsches, Robert Hermann
    Kandulski, Ole
    Fatum, Christian
    Koczan, Dirk
    Hartung, Hans-Peter
    Thiesen, Hans-Juergen
    Zettl, Uwe Klaus
    PLOS ONE, 2011, 6 (12):
  • [47] The Core of Gut Life: Firmicutes Profile in Patients with Relapsing-Remitting Multiple Sclerosis
    Kozhieva, Madina
    Naumova, Natalia
    Alikina, Tatiana
    Boyko, Alexey
    Vlassov, Valentin
    Kabilov, Marsel R.
    LIFE-BASEL, 2021, 11 (01): : 1 - 11
  • [48] In silico clinical trials for relapsing-remitting multiple sclerosis with MS TreatSim
    Sips, Fianne L. P.
    Pappalardo, Francesco
    Russo, Giulia
    Bursi, Roberta
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2022, 22 (SUPPL 6)
  • [49] Gene expression predicts clinical outcome of relapsing-remitting multiple sclerosis
    Achiron, A
    Gurevich, M
    Snir, Y
    Harrai, G
    Mandel, M
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 : S215 - S215
  • [50] Treatment of relapsing-remitting multiple sclerosis with fingolimod in routine clinical practice
    Alcala-Vicente, Carmen
    Perez-Miralles, Francisco C.
    Gascon-Gimenez, Francisco
    Bosca-Blasco, Isabel
    Navarre-Gimeno, Arantxa
    Coret-Ferrer, Francisco
    Casanova-Estruch, Bonaventura
    REVISTA DE NEUROLOGIA, 2017, 64 (10) : 445 - 453